{"title":"登革热","authors":"J. Ledermann, S. Abel","doi":"10.1542/9781581109870-part03-dengue","DOIUrl":null,"url":null,"abstract":"Since publication of his article, the author reports no further potential conflict of interest. 1. Gelmon KA, Tischkowitz M, Mackay H, et al. Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study. Lancet Oncol 2011;12:852-61. 2. The Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma. Nature 2011;474:609-15.","PeriodicalId":408207,"journal":{"name":"Red Book Informe 2015 del Comite sobre Enfermedades Infecciosas, 30.a edicion","volume":"37 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2015-11-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Dengue\",\"authors\":\"J. Ledermann, S. Abel\",\"doi\":\"10.1542/9781581109870-part03-dengue\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Since publication of his article, the author reports no further potential conflict of interest. 1. Gelmon KA, Tischkowitz M, Mackay H, et al. Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study. Lancet Oncol 2011;12:852-61. 2. The Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma. Nature 2011;474:609-15.\",\"PeriodicalId\":408207,\"journal\":{\"name\":\"Red Book Informe 2015 del Comite sobre Enfermedades Infecciosas, 30.a edicion\",\"volume\":\"37 1\",\"pages\":\"0\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2015-11-15\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Red Book Informe 2015 del Comite sobre Enfermedades Infecciosas, 30.a edicion\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1542/9781581109870-part03-dengue\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Red Book Informe 2015 del Comite sobre Enfermedades Infecciosas, 30.a edicion","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1542/9781581109870-part03-dengue","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
摘要
自他的文章发表以来，作者报告没有进一步的潜在利益冲突。1. Gelmon KA, Tischkowitz M, Mackay H，等。奥拉帕尼用于复发性高级别浆液性或低分化卵巢癌或三阴性乳腺癌患者:一项2期、多中心、开放标签、非随机研究中华医学杂志2011;12:852-61。2. 癌症基因组图谱研究网络。卵巢癌的综合基因组分析。自然2011;474:609-15。
Since publication of his article, the author reports no further potential conflict of interest. 1. Gelmon KA, Tischkowitz M, Mackay H, et al. Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study. Lancet Oncol 2011;12:852-61. 2. The Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma. Nature 2011;474:609-15.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
